Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Mar;182(3):530-531.
doi: 10.1111/bjd.18419. Epub 2019 Sep 4.

Tumour serine proteases C1r and C1s as novel biomarkers and therapeutic targets in invasive sporadic and recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma

Z Kopecki  1
Affiliations
Comment

Tumour serine proteases C1r and C1s as novel biomarkers and therapeutic targets in invasive sporadic and recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma

Z Kopecki. Br J Dermatol. 2020 Mar.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Riihilä P, Viiklepp K, Nissinen L et al. Tumour-cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma. Br J Dermatol 2020; 182:658-70.
    1. Boyle S, Kopecki Z. Mechanical force and actin dynamics during cutaneous squamous cell carcinoma (cSCC) progression: opportunities for new treatment modalities. In: Squamous Cell Carcinoma - Hallmark and treatment modalities. London: IntechOpen Limited, (forthcoming); chapter available as open access online at: https://doi.org/10.5772/intechopen.86041
    1. Fine JD, Bruckner-Tuderman L, Eady RA et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol 2014; 70:1103-26.
    1. Murray AS, Varela FA, List K. Type II transmembrane serine proteases as potential targets for cancer therapy. Biol Chem 2016; 397:815-26.
    1. Atanasova VS, Pourreyron C, Farshchian M et al. Identification of rigosertib for the treatment of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. Clin Cancer Res 2019; 25:3384-91.

Publication types